Safety Profile
Thymulin
Updated today
6/10Moderate
Regulatory Status
Not FDA-approved
Safety Summary
- Endogenous zinc-dependent thymic nonapeptide (FTS)
- low toxicity in animal models and a benign physiologic profile, but human safety/PK data is sparse and there is no established dose. Activity is inseparable from zinc status
- treat as experimental.
Thymulin's 6/10 rating reflects mixed evidence — some clinical data and a meaningful research base, but enough open questions that researchers should weight personal risk tolerance heavily. Long-term safety in the population segment most likely to use this compound (off-label) is the area with the thinnest published evidence.
Methodology
How we rate peptide safety
Every compound in our index gets a 1–10 safety score based on four weighted factors. The score reflects known research-use risk — not medical advice.
- 40% — Clinical evidence. Volume of peer-reviewed trials, sample sizes, duration, and consistency of outcomes. FDA-approved compounds anchor the top end (8–10); preclinical-only compounds cap at 6.
- 30% — Adverse-event profile. Severity and frequency of reported side effects, including GI events, cardiovascular signals, hypoglycemia, and long-term organ effects.
- 20% — Regulatory status. FDA approval, EMA approval, or status in active clinical trials. Compounds under safety warnings are penalized.
- 10% — Community-reported outcomes. Reddit, forum, and published case-report signal beyond formal trials. Used as a late-stage tiebreaker, not a leading factor.
9–10Well-studied, FDA-approvedLarge-trial evidence, established long-term safety. Examples: semaglutide, tesamorelin at approved doses.
7–8Mostly safe, some caveatsPhase 2/3 evidence or long community track record with known manageable side effects. Routine monitoring recommended.
5–6Mixed dataLimited clinical trials, mostly community/preclinical data. Real but uncertain risk profile.
3–4Caution advisedKnown side-effect patterns, thin safety data, or compounds under active regulatory scrutiny.
1–2Significant risk signalsDocumented serious adverse events (cardiovascular, hepatotoxicity, contamination) or withdrawn regulatory status.
Related compounds
Other compounds researchers compare with Thymulin
Safety ratings are derived from published clinical data, FDA approval status, and community-reported outcomes. They are not medical advice. Always consult a healthcare professional before using any research compound.